Could a new oral drug pass its first safety hurdle?

NCT ID NCT07765706

Not yet recruiting Knowledge-focused Sponsor: Insmed Incorporated Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This early-stage trial is testing an investigational drug called INS1033, given as an oral solution, to see if it is safe and well-tolerated in healthy adults. Participants receive either single or multiple rising doses of the drug or a placebo, and researchers monitor for side effects and measure drug levels in the blood. The goal is to gather initial safety data that could support future studies of INS1033 for potential medical use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: INS1033 (oral solution)
What this could lead to: If successful, this early trial could establish a safe dosing range for INS1033, paving the way for future studies in patients with specific diseases.
What could go wrong: This is a phase 1 trial in a small number of healthy people, so it can only assess safety and how the drug moves through the body—not whether it works for any condition. Side effects are possible, and the drug may not proceed to later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS

More trials for these conditions

Other studies related to the condition(s) this trial covers.